Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Autolus Therapeutics stock
Learn how to easily invest in Autolus Therapeutics stock.
Autolus Therapeutics plc is a biotechnology business based in the US. Autolus Therapeutics shares (AUTL) are listed on the NASDAQ and all prices are listed in US Dollars. Autolus Therapeutics employs 376 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Autolus Therapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – AUTL – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Autolus Therapeutics stock price (NASDAQ: AUTL)Use our graph to track the performance of AUTL stocks over time.
Autolus Therapeutics shares at a glance
|Latest market close||$4.41|
|52-week range||$4.44 - $9.40|
|50-day moving average||$5.91|
|200-day moving average||$6.14|
|Wall St. target price||$15.06|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.22|
Buy Autolus Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Autolus Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Autolus Therapeutics price performance over time
|1 week (2022-01-07)||-5.16%|
|1 month (2021-12-17)||-18.93%|
|3 months (2021-10-15)||-28.18%|
|6 months (2021-07-17)||-34.38%|
|1 year (2021-01-15)||-51.11%|
|2 years (2020-01-16)||-65.68%|
|3 years (2019-01-16)||30.87|
|5 years (2017-01-13)||N/A|
Autolus Therapeutics financials
|Revenue TTM||$2.6 million|
|Gross profit TTM||$-133,173,000|
|Return on assets TTM||-33.53%|
|Return on equity TTM||-59.51%|
|Market capitalisation||$342 million|
TTM: trailing 12 months
Autolus Therapeutics share dividends
We're not expecting Autolus Therapeutics to pay a dividend over the next 12 months.
Autolus Therapeutics share price volatility
Over the last 12 months, Autolus Therapeutics's shares have ranged in value from as little as $4.44 up to $9.4. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Autolus Therapeutics's is 1.4506. This would suggest that Autolus Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Autolus Therapeutics overview
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 and AUTO8 for the treatment of multiple myeloma; AUTO1/22 for the treatment of dual-targeting CAR-T; AUTO3NG for the treatment of hematological cancer; AUTO4 and AUTO5 for T cell lymphoma; AUTO6NG for the treatment of programmed T cell therapies; AUTO6 for the treatment of neuroblastoma; and AUTO7 for the treatment of prostate cancer. Autolus Therapeutics plc was founded in 2014 and is headquartered in London, the United Kingdom. .
Autolus Therapeutics in the news
Autolus Therapeutics (AUTL) Developing Next Generation Programmed T Cell Therapies (Slideshow)
Supreme Court vaccine mandate ruling won't bar companies from demanding Covid shots for workers — Biden vows to advocate for that
Autolus Therapeutics : announces retirement of chief financial officer and succession plan - Form 6-K
Frequently asked questionsWhat percentage of Autolus Therapeutics is owned by insiders or institutions?
Currently 25.23% of Autolus Therapeutics shares are held by insiders and 59.704% by institutions. How many people work for Autolus Therapeutics?
Latest data suggests 376 work at Autolus Therapeutics. When does the fiscal year end for Autolus Therapeutics?
Autolus Therapeutics's fiscal year ends in September. Where is Autolus Therapeutics based?
Autolus Therapeutics's address is: Forest House, London, United Kingdom, W12 7RZ What is Autolus Therapeutics's ISIN number?
Autolus Therapeutics's international securities identification number is: US05280R1005 What is Autolus Therapeutics's CUSIP number?
Autolus Therapeutics's Committee on Uniform Securities Identification Procedures number is: 05280R100
More guides on Finder
Donut savings review
Donut earns up to 10% APY, but you must have an iOS device.
Can Turo’s IPO do better than Uber and Airbnb?
Car-sharing service Turo has filed plans for an IPO. What you need to know.
Monie savings review
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Is Berkshire Hathaway the next $1 trillion stock?
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Tesla roars into 2022 after December drop
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
How to buy Affinia Therapeutics (AFTX) stock when it goes public
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
How to buy Austin Gold (AUST) stock when it goes public
Everything we know about the Austin Gold IPO, plus information on how to buy in.
How to buy VinFast stock when it goes public
Everything we know about the VinFast IPO, plus information on how to buy in.
NFT-funded LinksDAO moves $10.5 million closer to buying a golf course
Creating a golf club is a thus-far unique application of NFTs, and another step forward for the decentralized economy.
Ask an Expert